| | | |
CADM
|
α-MDA-5-positive
|
|---|
|
Population of area of residence (×1,000)
|
Total number of DM patients (M:F)
|
Mean age at onset (range)
|
Number (%) of patients (M:F)
|
Pvalue*
|
Mean age at onset (range)
|
Number (%) of patients (M:F)
|
Pvalue**
|
Mean age at onset (range)
|
|---|
|
T1 (0.5 to 108)
|
31 (4:27)
|
49.0 (4 to 70)
|
16 (51.6%) (1:15)
|
P for difference = 0.096
|
47.3 (4 to 69)
|
14 (45.2%) (1:13)
|
P for difference = 0.012
|
48.8 (20 to 66)
|
|
T2 (130 to 826)
|
26 (7:19)
|
44.0 (9 to 80)
|
10 (38.5%) (3:7)
|
P for trend = 0.031
|
40.0 (9 to 59)
|
7 (26.9%) (3:4)
|
P for trend = 0.003
|
39.9 (11 to 59)
|
|
T3 (2,200)
|
38 (17:21)
|
47.3 (1 to 79)
|
10 (26.3%) (4:6)
| |
45.9 (1 to 73)
|
5 (13.2%) (1:4)
| |
51.0 (39 to 63)
|
- CADM, clinically amyopathic dermatomyositis; DM, dermatomyositis; M:F, male:female; MDA-5, melanoma differentiation-associated gene 5. *Prevalence of CADM in total DM. **Prevalence of anti-MDA-5 in total DM.
